Top Markets
#1 Smilek to the Bank Smilek to the Bank +50.56%
#2 Purr Purr +48.38%
#3 龙虾 (Lobster) 龙虾 (Lobster) +22.75%
#4 DigiByte DigiByte +22.53%
#5 OriginTrail OriginTrail +21.47%
#6 Non-Playable Coin Non-Playable Coin +21.04%
#7 Pons Pons +19.40%
#8 ApeX ApeX +19.29%
#9 Zora Zora +18.63%
#10 Morpho Morpho +17.03%
Coin of the day
Smilek to the Bank Smilek to the Bank
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Rang în acțiuni #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Preț acțiune
$1.11
Ultima sincronizare: 2026-08-21
Capitalizare de piață
$100.55M
Schimbare (1 zi)
-7.69%
Schimbare (1 an)
-7.17%
Țară
TW
Tranzacționează Senhwa Biosciences, Inc. (6492)

Categorie

Healthcare
Venituri pentru Senhwa Biosciences, Inc. (6492)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Senhwa Biosciences, Inc., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Senhwa Biosciences, Inc. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH